Projects will be evaluated based on eligibility and scientific merit through independent peer review by a User Selection Panel. Feasibility and logistical requirements will be pre-screened based on part A, involving also the PRISMAP+ facilities concerned.
Project selection will also consider whether the applicant has benefitted or not from the PRISMAP+ services in the past, whether the project has the potential to attract the additional financial support required to fund the remaining project costs beyond the PRISMAP+ services, and whether the applicant is working in a country where radionuclide supply and biomedical laboratories, respectively, are not readily available.
Scientific merit will be measured based on Sections 1-4 of the proposal part B as outlined in Section 3 of the Guide for Applicants. A maximum of five points will be attributed to each Section (1: Insufficient, 2: Poor, 3: Satisfactory, 4: Good, 5: Excellent). All user projects reaching a minumum overall threshold are in principle eligible for PRISMAP+ funding and will be invited to hearings based on which the evaluation of all proposals of a user call will be finalised and proposals will be ranked and selected for funding.
Evaluation results will be made available within two months after the cut-off date of a call. The funded project needs to be started at the latest 12 months after selection for funding.
The User Selection Panel consists of six members of the PRISMAP+ consortium who contribute in particular with know-how on the techniques made available by PRISMAP+ and six external international scientific experts in the research fields of relevance to PRISMAP+.
PRISMAP coordinator and PRISMAP programme leader
Radionuclide production schedule and overall logistical chain including transport and applications
Nuclear medicine specialist with particular focus on radionuclide therapy and dosimetry and on amino acid PET imaging of brain tumours, PRISMAP ethics advisor.
Professor of Experimental Radiotherapeutics, Group Leader at Oxford Institute for Radiation Oncology, Honorary Consultant in Clinical Oncology at Oxford University Hospitals NHS Trust, radiopharm, new isotopes, therapy.
Life Sciences Department Head - R&D, Deputy Associate Laboratory Director - Life Sciences, Research interests in Targetry & Accelerator-Based Medical Isotope Development and in Nuclear Medicine.
Head of physics division, European academy of sciences (EURASC), fellow of the IEEE association, founder of the European Center for Research in Medical Imaging, SME representative, extensive experience with H2020 projects.
Former president of EANM, large network in NM, Head of Nuclear Medicine Department at AZ Delta, Nuclear Medicine Physician at UZ Brussel.
Professor of Nuclear Imaging and Therapy in Immuno-oncology, preclinical.
